HLA-E*0101 and HLA-G*010101 reduce the risk of Behcet's disease

Tissue Antigens

Volumn 69, Issue 2, 2007, Pages 139-144

  Park, K S ^a   Park, J S ^a   Nam, J H ^a   Bang, D ^b   Sohn, S ^c   Lee, E S ^d  

^a Sungshin Women's University   (South Korea)

^b Yonsei University   (South Korea)

^c Ajou University   (South Korea)

^d Ajou University School of Medicine   (South Korea)

Author keywords

Behcet's disease; Genetic susceptibility; HLA E; HLA G

Indexed keywords

HLA E ANTIGEN; HLA G ANTIGEN; HLA ANTIGEN; HLA E*0101 ANTIGEN; HLA G*010101 ANTIGEN; HLA-E*0101 ANTIGEN; HLA-G*010101 ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK REDUCTION; ALLELE; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; LYMPHOCYTE; RISK;

ALLELES; BEHCET SYNDROME; GENE FREQUENCY; HLA ANTIGENS; HUMANS; LYMPHOCYTES; POLYMORPHISM, GENETIC; RISK;

EID: 33846609246     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2006.00742.x     Document Type: Article

References (35)

1. Accardo-Palumbo A, Ferrante A, Cadelo M et al. The level of soluble granzyme A is elevated in the plasma and in the Vg9/Vd2 T cell culture supernatants of patients with active Behcet's disease. Clin Exp Rheumatol 2004: 22 (Suppl 34): S45-9.
2. Suzuki N, Nara K, Suzuki T. Skewed Th1 responses caused by excessive expression of Txk, a member of the Tec family of tyrosine kinases, in patients with Behcet's disease. Clin Med Res 2006: 4: 147-51.
3. Takeno M, Shimoyama Y, Kashiwakura JI, Nagafuchi H, Sakane T, Suzuki N. Abnormal killer inhibitory receptor expression on natural killer cells in patients with Behcet's disease. Rheumatol Int 2004: 24: 212-6.
4. Nagafuchi H, Takeno M, Yoshikawa H et al. Excessive expression of Txk, a member of the Tec family of tyrosine kinases, contributes to excessive Th1 cytokine production by T lymphocytes in patients with Behcet's disease. Clin Exp Immunol 2005: 139: 363-70.
5. Mizuki N, Ota M, Katsuyama Y et al. Association analysis between the MIC-A and HLA-B alleles in Japanese patients with Behcet's disease. Arthritis Rheum 1999: 42: 1961-6.
6. Hoare HL, Sullivan LC, Pietra G et al. Structural basis for a major histocompatibility complex class Ib-restricted T cell response. Nat Immunol 2006: 7: 256-64.
7. Lee N, Llano M, Carretero M et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A 1998: 95: 5199-204.
8. Kaiser BK, Barahmand-Pour F, Paulsene W, Medley S, Geraghty DE, Strong RK. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J Immunol 2005: 174: 2878-84.
9. Park GM, Lee S, Park B, Kim E, Shin J, Cho K, Ahn K. Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun 2004: 313: 606-11.
10. Ulbrecht M, Rehberger B, Strobel I et al. HLA-G: expression in human keratinocytes in vitro and in human skin in vivo. Eur J Immunol 1994: 24: 176-80.
11. Shiroishi M, Tsumoto K, Amano K et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A 2003: 100: 8856-61.
12. Llano M, Lee N, Navarro F et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol 1998: 28: 2854-63.
13. Rajagopalan S, Bryceson YT, Kuppusamy SP et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol 2006: 44: 70-86.
14. Fournel S, Aguerre-Girr M, Huc X et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD81 cells by interacting with CD8. J Immunol 2000: 164: 6100-4.
15. O'Callaghan CA. Molecular basis of human natural killer cell recognition of HLA-E (human leucocyte antigen-E) and its relevance to clearance of pathogen-infected and tumour cells. Clin Sci (Lond) 2000: 99: 9-17.
16. Michaelsson J, Teixeira de Matos C, Achour A, Lanier LL, Karre K, Soderstrom K. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med 2002: 196: 1403-14.
17. Ulbrecht M, Couturier A, Martinozzi S et al. Cell surface expression of HLA-E: inter-action with human b2-microglobulin and allelic differences. Eur J Immunol 1999: 29: 537-47.
18. Strong RK, Holmes MA, Li P, Braun L, Lee N, Geraghty DE. HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. J Biol Chem 2003: 278: 5082-90.
19. Hviid TV, Hylenius S, Rorbye C, Nielsen LG. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics 2003: 55: 63-79.
20. Hylenius S, Andersen AM, Melbye M, Hviid TV. Association between HLA-G genotype and risk of pre-eclampsia: a case-control study using family triads. Mol Hum Reprod 2004: 10: 237-46.
21. Rousseau P, Le Discorde M, Mouillot G, Marcou C, Carosella ED, Moreau P. The 14 bp deletion-insertion polymorphism in the 3′ UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol 2003: 64: 1005-10.
22. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990: 335: 1078-80.
23. Matte C, Lacaille J, Zijenah L, Ward B, Roger M. HLA-G and HLA-E polymorphisms in an indigenous African population. The ZVITAMBO Study Group. Hum Immunol 2000: 61: 1150-6.
24. Gazit E, Slomov Y, Goldberg I, Brenner S, Loewenthal R. HLA-G is associated with pemphigus vulgaris in Jewish patients. Hum Immunol 2004: 65: 39-46.
25. Hviid TV, Hylenius S, Hoegh AM, Kruse C, Christiansen OB. HLA-G polymorphisms in couples with recurrent spontaneous abortions. Tissue Antigens 2002: 60: 122-32.
26. Hviid TV. HLA-G in human reproduction: aspects of genetics, function and pregnancy complications. Hum Reprod Update 2006: 12: 209-32.
27. Maier S, Grzeschik M, Weiss EH, Ulbrecht M. Implications of HLA-E allele expression and different HLA-E ligand diversity for the regulation of NK cells. Hum Immunol 2000: 61: 1059-65.
28. Kanai T, Fujii T, Keicho N et al. Polymorphism of human leukocyte antigen-E gene in the Japanese population with or without recurrent abortion. Am J Reprod Immunol 2001: 45: 168-73.
29. Gomez-Casado E, Martinez-Laso J, Vargas-Alarcon G et al. Description of a new HLA-E (E*01031) allele and its frequency in the Spanish population. Hum Immunol 1997: 54: 69-73.
30. Navarro F, Llano M, Bellon T, Colonna M, Geraghty DE, Lopez-Botet M. The ILT2 (LIR1) and CD94/NKG2ANKcell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol 1999: 29: 277-83.
31. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 1999: 189: 1093-100.
32. Hviid TV, Rizzo R, Melchiorri L, Stignani M, Baricordi OR. Polymorphism in the 5′ upstream regulatory and 3′ untranslated regions of the HLA-G gene in relation to soluble HLA-G and IL-10 expression. Hum Immunol 2006: 67: 53-62.
33. Solier C, Mallet V, Lenfant F, Bertrand A, Huchenq A, Le Bouteiller P. HLA-G unique promoter region: functional implications. Immunogenetics 2001: 53: 617-25.
34. Kapasi K, Albert SE, Yie S, Zavazava N, Librach CL. HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. Immunology 2000: 101: 191-200.
35. Rebmann V, van der Ven K, Passler M, Pfeiffer K, Krebs D, Grosse-Wilde H. Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens 2001: 57: 15-21.